1
|
Granat MM, Eifler-Zydel J, Kolmas J. Statins-Their Role in Bone Tissue Metabolism and Local Applications with Different Carriers. Int J Mol Sci 2024; 25:2378. [PMID: 38397055 PMCID: PMC10888549 DOI: 10.3390/ijms25042378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2024] [Revised: 02/13/2024] [Accepted: 02/15/2024] [Indexed: 02/25/2024] Open
Abstract
Statins, widely prescribed for lipid disorders, primarily target 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase competitively and reversibly, resulting in reduced low-density lipoprotein cholesterol (LDL-C). This mechanism proves effective in lowering the risk of lipid-related diseases such as ischemic cerebrovascular and coronary artery diseases. Beyond their established use, statins are under scrutiny for potential applications in treating bone diseases. The focus of research centers mainly on simvastatin, a lipophilic statin demonstrating efficacy in preventing osteoporosis and aiding in fracture and bone defect healing. Notably, these effects manifest at elevated doses (20 mg/kg/day) of statins, posing challenges for systematic administration due to their limited bone affinity. Current investigations explore intraosseous statin delivery facilitated by specialized carriers. This paper outlines various carrier types, characterizing their structures and underscoring various statins' potential as local treatments for bone diseases.
Collapse
Affiliation(s)
- Marcin Mateusz Granat
- Department of Clinical and Experimental Pharmacology, Faculty of Medicine, Medical University of Warsaw, Banacha 1 Str., 02-097 Warsaw, Poland;
| | - Joanna Eifler-Zydel
- Department of Pharmaceutical Chemistry and Biomaterials, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Str., 02-097 Warsaw, Poland;
| | - Joanna Kolmas
- Department of Pharmaceutical Chemistry and Biomaterials, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Str., 02-097 Warsaw, Poland;
| |
Collapse
|
2
|
Issa DR, Elamrousy W, Gamal AY. Alveolar ridge splitting and simvastatin loaded xenograft for guided bone regeneration and simultaneous implant placement: randomized controlled clinical trial. Clin Oral Investig 2024; 28:71. [PMID: 38172458 DOI: 10.1007/s00784-023-05427-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Accepted: 11/20/2023] [Indexed: 01/05/2024]
Abstract
OBJECTIVES The present study goal was to assess clinically and radiographically using simvastatin (SMV) loaded xenograft for guided bone regeneration (GBR) around simultaneously placed implants with alveolar ridge splitting in patients with horizontally atrophic jaw defect. MATERIALS AND METHODS Randomized distribution of the twenty-two patients into two groups (11 patients each) was performed. Group I participants received alveolar ride splitting (ARS) with GBR using SMV gel mixed bone graft and a barrier membrane with simultaneous implant placement. Group II received the same treatment protocol without SMV gel. At the baseline, 6- and 9-months post-surgery, clinical and radiological alterations were assessed. RESULTS Six months after therapy, PES records of group I were statistically significantly improved than those of group II (P < .001). Group I exhibited statistically significant expansion of the alveolar ridge over group II after 6 and 9 months (P < .001). When compared to group II over the evaluation interval between 6 and 9 months, group I demonstrated statistically substantially minimal loss of the mean marginal bone level (P < .001). At the 6- and 9-month observation periods, bone density gain was considerably higher in group I than that in group II (P < .001). CONCLUSION Alveolar ridge splitting along with GBR-augmented SMV improve the clinical and radiographical outcomes around dental implant over GBR alone. CLINICAL RELEVANCE Augmenting GBR with SMV in alveolar ridge splitting could boost implant osseointegration and enhance peri-implant tissue changes. CLINICAL TRIAL REGISTRATION NCT05020405.
Collapse
Affiliation(s)
- Dalia Rasheed Issa
- Department of Oral Medicine and Periodontology, Faculty of Oral and Dental Medicine, Kafrelsheikh University, Kafr El-Sheikh, Egypt.
- Department of Periodontics and Preventive Dentistry, School of Dental Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
| | - Walid Elamrousy
- Department of Oral Medicine and Periodontology, Faculty of Oral and Dental Medicine, Kafrelsheikh University, Kafr El-Sheikh, Egypt
| | - Ahmed Y Gamal
- Department of Periodontology, Faculty of Oral and Dental Medicine, Ain Shams University-Misr University for Science and Technology, Cairo, Egypt
| |
Collapse
|
3
|
Cheng Y, Jin W, Zheng L, Huang X, Luo S, Hong W, Liao J, Samruajbenjakun B, Leethanakul C. The role of autophagy in SIM mediated anti-inflammatory osteoclastogenesis through NLRP3 signaling pathway. Immun Inflamm Dis 2024; 12:e1145. [PMID: 38270300 PMCID: PMC10777745 DOI: 10.1002/iid3.1145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 11/23/2023] [Accepted: 12/26/2023] [Indexed: 01/26/2024] Open
Abstract
BACKGROUND Inflammatory bone resorption is a prominent risk factor for implantation failure. Simvastatin (SIM) has anti-inflammatory effects independent of cholesterol lowering and reduces osteoclastogenesis by decreasing both the number and activity of osteoclasts. However, the specific mechanism of inflammatory bone loss alleviation by SIM remains to be elucidated. We hypothesized that SIM relieves inflammatory bone loss by modulating autophagy and suppressing the NOD-like receptor family pyrin domain-containing protein 3 (NLRP3) signaling pathway. METHODS AND RESULTS RAW264.7 cells were stimulated by lipopolysaccharide (LPS) after being pretreated with various concentrations of SIM. Osteoclast (OC) differentiation, formation and activity were evaluated by tartrate-resistant acid phosphatase staining, F-actin ring staining and bone resorption pit assays, respectively. We observed autophagosomes by transmission electron microscopy. Then NLRP3 inhibitor MCC950 was used to further explore the corresponding molecular mechanism underlying anti-inflammatory bone resorption, the expression of autophagy-related proteins and NLRP3 signaling pathway factors in pre-OCs were evaluated by western blot analysis, and the expression of OC-specific molecules was analyzed using reverse transcription-quantitative polymerase chain reaction. The results showed that SIM decreased the expression of tumor necrosis factor-α, whereas increased Interleukin-10. In addition, SIM inhibited LPS-induced OC differentiation, formation, bone resorption activity, the level of autophagosomes, and OC-specific markers. Furthermore, SIM significantly suppressed autophagy by downregulating LC3II, Beclin1, ATG7, and NLRP3-related proteins expression while upregulating P62 under inflammatory conditions. CONCLUSIONS SIM may reduce autophagy secretion to attenuate LPS-induced osteoclastogenesis and the NLRP3 signaling pathway participates in this process, thus providing theoretical basis for the application of this drug in peri-implantitis.
Collapse
Affiliation(s)
- Yuting Cheng
- Faculty of DentistryPrince of Songkla UniversityHat YaiThailand
- School/Hospital of StomatologyGuizhou Medical UniversityGuiyangChina
| | - Wenjun Jin
- School/Hospital of StomatologyGuizhou Medical UniversityGuiyangChina
| | - Lin Zheng
- School/Hospital of StomatologyGuizhou Medical UniversityGuiyangChina
| | | | - Shanshan Luo
- School/Hospital of StomatologyGuizhou Medical UniversityGuiyangChina
| | - Wei Hong
- Key Laboratory of Endemic and Ethnic Diseases, Ministry of EducationGuizhou Medical UniversityGuiyangChina
| | - Jian Liao
- School/Hospital of StomatologyGuizhou Medical UniversityGuiyangChina
| | | | | |
Collapse
|
4
|
Kumaar NR, Nair SC. Nanomaterials: an intra-periodontal pocket drug-delivery system for periodontitis. Ther Deliv 2023; 14:227-249. [PMID: 37291865 DOI: 10.4155/tde-2023-0001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023] Open
Abstract
Periodontitis is a microbiological condition that affects the tissues supporting the teeth. The fundamental to effective periodontal therapy is choosing the suitable antimicrobial and anti-inflammatory agent, together with the proper route of drug administration and delivery system. Intra-periodontal pocket approach with nano drug-delivery systems (NDDS) such as polymeric nanoparticles, gold nanoparticles, silica nanoparticles, magnetic nanoparticles, liposomes, polymersomes, exosomes, nano micelles, niosome, solid lipid nanoparticles, nano lipid carriers, nanocomposites, nanogels, nanofibers, scaffolds, dendrimers, quantum dots, etc., will be appropriate route of drug administration and delivery system. This NDDS delivers the drugs at the site of infection to inhibit growth and promote tissue regeneration. The present review focused on providing comprehensive information on the NDDS for periodontitis, which enhanced therapeutic outcomes via intra-periodontal pocket delivery.
Collapse
Affiliation(s)
- Nethish R Kumaar
- Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala, 682041, India
| | - Sreeja C Nair
- Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala, 682041, India
| |
Collapse
|
5
|
Kaur M, Nagpal M, Grewal AK, Chauhan S, Dora CP, Singh TG. Molecular Complex of HSIM-loaded Polymeric Nanoparticles: Potential Carriers in Osteoporosis. Curr Drug Targets 2023; 24:1066-1078. [PMID: 37718521 DOI: 10.2174/1389450124666230915092910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Revised: 07/03/2023] [Accepted: 08/24/2023] [Indexed: 09/19/2023]
Abstract
BACKGROUND Statins, especially simvastatin promote bone formation by stimulating the activity of osteoblasts and suppressing osteoclast activity via the BMP-Smad signaling pathway. Statins present the liver first-pass metabolism. This study attempts to fabricate and evaluate simvastatin functionalized hydroxyapatite encapsulated in poly(lactic-co-glycolic) acid (PLGA) nanoparticles (HSIM-PLGA NPs) administered subcutaneously with sustained release properties for effective management of osteoporosis. METHODS Simvastatin functionalized hydroxyapatite (HSIM) was prepared by stirring and validated by docking studies, Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and X-ray diffraction (XRD). Further, HSIM-loaded PLGA nanoparticles (HSIM-PLGA NPs) were developed via the solvent emulsification method. The nanoparticles were evaluated for zeta potential, particle size, entrapment efficiency, stability studies, and in vitro drug release studies. in vitro binding affinity of nanoparticles for hydroxyapatite was also measured. Bone morphology and its effect on bone mineral density were examined by using a glucocorticoid-induced osteoporosis rat model. RESULTS The optimized nanoparticles were found to be amorphous and showed no drug-polymer interaction. The particle size of formulated nanoparticles varied from 196.8 ± 2.27nm to 524.8 ± 5.49 nm and the entrapment efficiency of nanoparticles varied from 41.9 ± 3.44% to 70.8 ± 4.46%, respectively. The nanoparticles showed sustained release behaviour (75% in 24 hr) of the drug followed by non-fickian drug release. The nanoparticles exhibited high binding affinity to bone cell receptors, increasing bone mineral density. A significant difference in calcium and phosphorous levels was observed in disease and treatment rats. Porous bone and significant improvement in porosity were observed in osteoporotic rats and treated rats, respectively (P < 0.05). CONCLUSION Bone-targeting nanoparticles incorporating functionalized simvastatin can target bone. Thus, in order to distribute simvastatin subcutaneously for the treatment of osteoporosis, the developed nanoparticles may act as a promising approach.
Collapse
Affiliation(s)
- Malkiet Kaur
- Chitkara College of Pharmacy, Chitkara University, Punjab, India
| | - Manju Nagpal
- Chitkara College of Pharmacy, Chitkara University, Punjab, India
| | | | - Samrat Chauhan
- Chitkara College of Pharmacy, Chitkara University, Punjab, India
| | | | | |
Collapse
|
6
|
Formulation of simvastatin chitosan nanoparticles for controlled delivery in bone regeneration: Optimization using Box-Behnken design, stability and in vivo study. Int J Pharm 2020; 577:119038. [DOI: 10.1016/j.ijpharm.2020.119038] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Revised: 01/08/2020] [Accepted: 01/11/2020] [Indexed: 12/18/2022]
|
7
|
Tao S, Chen SQ, Zhou WT, Yu FY, Bao L, Qiu GX, Qiao Q, Hu FQ, Wang JW, Yuan H. A novel biocompatible, simvastatin-loaded, bone-targeting lipid nanocarrier for treating osteoporosis more effectively. RSC Adv 2020; 10:20445-20459. [PMID: 35517758 PMCID: PMC9054278 DOI: 10.1039/d0ra00685h] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 07/16/2020] [Accepted: 05/11/2020] [Indexed: 12/16/2022] Open
Abstract
An insufficient drug concentration at the target site and drug efflux resulting in poor efficacy are recognized as important obstacles in osteoporosis treatment. Simvastatin (SIM), which can treat osteoporosis by promoting osteoblast differentiation and mineralization through the bone morphogenetic proteins (BMP)-Smad signaling pathway, has lower bioavailability, and less bone tissue distribution. Herein, novel lipid nanoparticles (LNPs) delivering SIM (SIM/LNPs) for osteoporosis therapy were developed with aspartic oligopeptide (ASPn, here ASP6)-based bone-targeting moieties grafted to the nanoparticles (SIM/ASP6-LNPs) in an attempt to increase the concentration of SIM in bones with a relatively low dose to minimize adverse effects. In vivo experiments indicated that the ASP6-LNPs exhibited ideal bone-targeting characteristics, and in vitro cell evaluation experiments showed LNPs have good biocompatibility with MC3T3-E1 cells. The cell mineralization experiment revealed that the SIM-loaded LNPs induced osteoblast differentiation and the formation of mineralized nodules in MC3T3-E1 cells, achieving the same efficacy as that of SIM. Pharmacodynamic experiments revealed that SIM/ASP6-LNPs improved the efficacy of SIM on the recovery of bone mineral density when compared to SIM/LNPs or to SIM alone. Therefore, SIM/ASP6-LNPs may represent a potential bone-targeting drug delivery system (DDS) that contributes to the development of a novel osteoporosis treatment. A scheme of the preparation of SIM/ASP6-LNPs and a mechanism which indicated that SIM/ASP6-LNPs could improve the efficacy of SIM on the recovery of osteoporosis under the action of bone-targeting moieties ASP6.![]()
Collapse
Affiliation(s)
- Shan Tao
- College of Pharmaceutical Sciences
- Zhejiang University
- Hangzhou
- China
| | - Shao-qing Chen
- College of Pharmaceutical Sciences
- Zhejiang University
- Hangzhou
- China
| | - Wen-tao Zhou
- College of Pharmaceutical Sciences
- Zhejiang University
- Hangzhou
- China
| | - Fang-ying Yu
- College of Pharmaceutical Sciences
- Zhejiang University
- Hangzhou
- China
| | - Lu Bao
- College of Pharmaceutical Sciences
- Zhejiang University
- Hangzhou
- China
| | - Guo-xi Qiu
- College of Pharmaceutical Sciences
- Zhejiang University
- Hangzhou
- China
| | - Qing Qiao
- Anesthesia Department
- Zhejiang University School of Medicine
- Sir Run Run Shaw Hospital
- Hangzhou
- China
| | - Fu-qiang Hu
- College of Pharmaceutical Sciences
- Zhejiang University
- Hangzhou
- China
| | - Jian-wei Wang
- Department of Orthopaedics
- The Second Affiliated Hospital of Zhejiang University School of Medicine
- Hangzhou
- China
| | - Hong Yuan
- College of Pharmaceutical Sciences
- Zhejiang University
- Hangzhou
- China
| |
Collapse
|
8
|
Raillard M, Detotto C, Grepper S, Beslac O, Fujioka-Kobayashi M, Schaller B, Saulacic N. Anaesthetic and Perioperative Management of 14 Male New Zealand White Rabbits for Calvarial Bone Surgery. Animals (Basel) 2019; 9:ani9110896. [PMID: 31683852 PMCID: PMC6912242 DOI: 10.3390/ani9110896] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Revised: 10/18/2019] [Accepted: 10/22/2019] [Indexed: 11/30/2022] Open
Abstract
Simple Summary Bone substitutes are commonly used when bone grafts are necessary in human craniofacial surgery. To study the properties and biologic behaviour of those substitutes, they can be implanted in experimental animals. A frequently used model involves the creation of critical-sized defects (defects that are too large to heal by themselves) in the rabbits calvaria (the top part of the skull). The procedure was initially described in 1989 and the authors considered and reported that post-operative analgesia was not necessary. In our experience, this procedure is invasive and can result in severe postoperative pain. The anaesthetic management of rabbits undergoing this procedure is challenging. Most of the recent publications using this model fail to provide sufficient information on perioperative animal management. With this report we have aimed to document a possible practical and simple anaesthetic and postoperative management of rabbits undergoing this procedure. Particular emphasis has been placed on postoperative pain assessment, duration and treatment. Abstract Calvarial bone surgery on rabbits is frequently performed. This report aims to document a simple and practical anaesthetic and perioperative management for this procedure. Fourteen male New Zealand white rabbits were included in the study. Subcutaneous (SC) dexmedetomidine, ketamine and buprenorphine ± isoflurane vaporized in oxygen administered through a supraglottic airway device (V-gel®) provided clinically suitable anaesthesia. Supplemental oxygen was administered throughout recovery. Monitoring was clinical and instrumental (pulse-oximetry, capnography, invasive blood pressure, temperature, arterial blood gas analysis). Lidocaine was infiltrated at the surgical site and meloxicam was injected subcutaneously as perioperative analgesia. After surgery, pain was assessed five times daily (composite behavioural pain scale and grimace scale). Postoperative analgesia included SC meloxicam once daily for four days and buprenorphine every 8 h for three days (unless both pain scores were at the lowest possible levels). Rescue analgesia (buprenorphine) was administered in case of the score > 3/8 in the composite pain scale, >4/10 on the grimace scale or if determined necessary by the caregivers. Airway management with a V-gel® was possible but resulted in respiratory obstruction during the surgery in two cases. Hypoventilation was observed in all rabbits. All rabbits experienced pain after the procedure. Monitoring, pain assessments and administration of postoperative analgesia were recommended for 48 h.
Collapse
Affiliation(s)
- Mathieu Raillard
- Experimental Surgery Facility (ESF), Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.
- Vetsuisse Faculty, Department of Clinical Veterinary Medicine, Institute of Anaesthesiology and Pain Therapy, University of Bern, 3012 Bern, Switzerland.
- School of Veterinary Science, Faculty of Science, The University of Sydney, Sydney 2006, Australia.
| | - Carlotta Detotto
- Experimental Surgery Facility (ESF), Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.
- Central Animal Facilities, Department for BioMedical Research, University of Bern, 3008 Bern, Switzerland.
| | - Sandro Grepper
- Central Animal Facilities, Department for BioMedical Research, University of Bern, 3008 Bern, Switzerland.
| | - Olgica Beslac
- Experimental Surgery Facility (ESF), Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.
| | - Masako Fujioka-Kobayashi
- Department of Cranio-Maxillofacial Surgery, Inselspital Bern, University Hospital, University of Bern, 3008 Bern, Switzerland.
| | - Benoit Schaller
- Department of Cranio-Maxillofacial Surgery, Inselspital Bern, University Hospital, University of Bern, 3008 Bern, Switzerland.
| | - Nikola Saulacic
- Department of Cranio-Maxillofacial Surgery, Inselspital Bern, University Hospital, University of Bern, 3008 Bern, Switzerland.
| |
Collapse
|
9
|
Huang Y, Lin Y, Rong M, Liu W, He J, Zhou L. 20(S)-hydroxycholesterol and simvastatin synergistically enhance osteogenic differentiation of marrow stromal cells and bone regeneration by initiation of Raf/MEK/ERK signaling. JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE 2019; 30:87. [PMID: 31325047 DOI: 10.1007/s10856-019-6284-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2018] [Accepted: 06/24/2019] [Indexed: 06/10/2023]
Abstract
Previous studies have demonstrated the significant roles of simvastatin (SVA) and oxysterols in the osteogenesis process. In this study, we evaluate the effect of a combination of SVA and 20(S)-hydroxycholesterol (20(S)OHC) on the cell viability and osteogenic differentiation of bone marrow stromal cells (BMSCs). After treatment with a control vehicle, SVA (0.025, 0.10, 0.25 or 1.0 μM), 20(S)OHC (5 μM), or a combination of both (0.25 μM SVA + 5 μM 20(S)OHC), the proliferation, apoptosis, ALP activity, mineralization, osteogenesis-related gene expression and Raf/MEK/ERK signaling activity in BMSCs were measured. Our results showed that high concentrations of SVA (0.25 and 1.0 μM) enhanced osteogenesis-related genes expression while attenuating cell viability. The addition of 5 μM 20(S)OHC induced significantly higher proliferative activity, which neutralized the inhibitory effect of SVA on the viability of BMSCs. Moreover, compared to supplementation with only one of the additives, combined supplementation with both SVA and 20(S)OHC induced significantly enhanced ALP activity, calcium sedimentation, osteogenesis-related genes (ALP, OCN and BMP-2) expression and Raf/MEK/ERK signaling activity in BMSCs; these enhancements were attenuated by treatment with the inhibitor U0126, indicating a significant role of Raf/MEK/ERK signaling in mediating the synergistically enhanced osteogenic differentiation of BMSCs by combined SVA and 20(S)OHC treatment. Additionally, histological examination confirmed a synergistic effect of SVA and 20(S)OHC on enhancing bone regeneration in a rabbit calvarial defect model. This newly developed SVA/20(S)OHC formulation may be used as an osteoinductive drug to enhance bone healing.
Collapse
Affiliation(s)
- Yinghe Huang
- Center of Oral Implantology, Stomatological Hospital, Southern Medical University, 366 South Jiangnan Road, Guangzhou, 510280, Guangdong, China
- The Department of Stomatology, Taishan People's Hospital, Affiliated to Guangdong Medical University, Taishan, Guangdong, China
| | - Yao Lin
- The Department of Stomatology, Jieyang Affiliated Hospital, SunYat-sen University, Jieyang, Guangdong, China
| | - Mingdeng Rong
- Center of Oral Implantology, Stomatological Hospital, Southern Medical University, 366 South Jiangnan Road, Guangzhou, 510280, Guangdong, China
| | - Weizhen Liu
- Center of Oral Implantology, Stomatological Hospital, Southern Medical University, 366 South Jiangnan Road, Guangzhou, 510280, Guangdong, China
| | - Junbing He
- The Department of Stomatology, Jieyang Affiliated Hospital, SunYat-sen University, Jieyang, Guangdong, China
| | - Lei Zhou
- Center of Oral Implantology, Stomatological Hospital, Southern Medical University, 366 South Jiangnan Road, Guangzhou, 510280, Guangdong, China.
| |
Collapse
|
10
|
O'Neill E, Rajpura K, Carbone EJ, Awale G, Kan HM, Lo KWH. Repositioning Tacrolimus: Evaluation of the Effect of Short-Term Tacrolimus Treatment on Osteoprogenitor Cells and Primary Cells for Bone Regenerative Engineering. Assay Drug Dev Technol 2019; 17:77-88. [DOI: 10.1089/adt.2018.876] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Affiliation(s)
- Edward O'Neill
- Institute for Regenerative Engineering, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- The Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- Division of Endocrinology, Department of Medicine, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
| | - Komal Rajpura
- Institute for Regenerative Engineering, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- The Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- Connecticut Institute for Clinical and Translational Science, University of Connecticut Health Center, Farmington, Connecticut
| | - Erica J. Carbone
- Institute for Regenerative Engineering, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- The Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- Division of Endocrinology, Department of Medicine, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- UConn Stem Cell Institute, University of Connecticut Health Center, Farmington, Connecticut
| | - Guleid Awale
- Institute for Regenerative Engineering, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- The Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
| | - Ho-Man Kan
- Institute for Regenerative Engineering, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- The Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- Department of Orthopaedic Surgery, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
| | - Kevin W.-H. Lo
- Institute for Regenerative Engineering, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- The Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- Division of Endocrinology, Department of Medicine, University of Connecticut Health Center, School of Medicine, Farmington, Connecticut
- Connecticut Institute for Clinical and Translational Science, University of Connecticut Health Center, Farmington, Connecticut
- UConn Stem Cell Institute, University of Connecticut Health Center, Farmington, Connecticut
| |
Collapse
|
11
|
Tawfik MS, Abdel-Ghaffar KA, Gamal AY, El-Demerdash FH, Gad HA. Lycopene solid lipid microparticles with enhanced effect on gingival crevicular fluid protein carbonyl as a biomarker of oxidative stress in patients with chronic periodontitis. J Liposome Res 2019; 29:375-382. [DOI: 10.1080/08982104.2019.1566243] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- Maie S. Tawfik
- Department of Periodontology, Faculty of Dental Medicine, Ain Shams University, Cairo, Egypt
| | - Khaled A. Abdel-Ghaffar
- Department of Periodontology, Faculty of Dental Medicine, Ain Shams University, Cairo, Egypt
| | - Ahmed Y. Gamal
- Department of Periodontology, Faculty of Dental Medicine, Ain Shams University, Cairo, Egypt
| | - Fatma H. El-Demerdash
- Department of Periodontology, Faculty of Dental Medicine, Ain Shams University, Cairo, Egypt
| | - Heba A. Gad
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
| |
Collapse
|
12
|
Niu M, Feng X, Zhou L. The role of the ERK1/2 pathway in simvastatin-loaded nanomicelles and simvastatin in regulating the osteogenic effect in MG63 cells. Int J Nanomedicine 2018; 13:8165-8178. [PMID: 30584296 PMCID: PMC6287536 DOI: 10.2147/ijn.s182998] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Objectives The present study aimed to clarify the role of the ERK1/2 pathway in simvastatin (SV)-loaded nanomicelles (SVNs)- and SV-mediated promotion of cell osteogenic differentiation and explore the molecular mechanisms by which SVNs exhibited a greater efficacy in promoting osteogenic differentiation than SV. Materials and methods SVNs were synthesized using a dialysis method. MG63 cells were treated with 2.5, 0.25, and 0.025 μmol/L of the drug. The optimal drug dosage was determined by examining the proliferative activity and ALP activity of the MG63 cells. Subsequently, Western blot analysis was performed to analyze the levels of the phosphorylated ERK1/2 proteins in each experimental group at various time points. Finally, the inhibitor PD98059 was used to effectively inhibit the ERK1/2 pathway. The resulting changes in the proliferative activity of MG63 cells and the osteogenesis-related markers were analyzed. Results The SVNs synthesized in the present study had a mean diameter of 27 nm. The encapsulation and drug-loading efficiencies were 52.03% ± 4.05% and 9.42% ± 0.66%, respectively. SVNs and SV exhibited optimum osteogenesis-promoting effects when the drugs were administered at a concentration of 0.25 μmol/L. The drug-induced activation of the ERK1/2 pathway reached a peak at 15 minutes after administration and then declined rapidly. From 24 hours to 7 days, SVNs and SV exerted an inhibitory effect on the ERK1/2 pathway rather than an activating effect. Throughout the whole experimental process, the regulatory effect of SVNs on the ERK1/2 pathway was significantly greater than that of SV. Inhibition of the ERK1/2 pathway by PD98059 markedly reduced the proliferative activity of the cells in all experimental groups. In addition, the ALP activity and the expression levels of the osterix (OSX) and osteocalcin (OC) proteins were drastically increased. Conclusion SVNs significantly increased the effect of SV-induced osteogenic differentiation by strongly inhibiting the ERK1/2 pathway.
Collapse
Affiliation(s)
- Mao Niu
- Department of Stomatology, School of Medical Technology and Nursing, Shenzhen Polytechnic, Shenzhen, 518055, China
| | - Xianling Feng
- Department of Pathology, School of Medical, Shenzhen University, Shenzhen, 518060, China
| | - Lei Zhou
- Center of Oral Implantology, Guangdong Provincial Stomatological Hospital, Southern Medical University, Guangzhou, 510280, China,
| |
Collapse
|
13
|
Xu R, Shi G, Xu L, Gu Q, Fu Y, Zhang P, Cheng J, Jiang H. Simvastatin improves oral implant osseointegration via enhanced autophagy and osteogenesis of BMSCs and inhibited osteoclast activity. J Tissue Eng Regen Med 2018; 12:1209-1219. [PMID: 29498229 DOI: 10.1002/term.2652] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 02/07/2018] [Accepted: 02/17/2018] [Indexed: 02/06/2023]
Affiliation(s)
- Rongyao Xu
- Jiangsu Key Laboratory of Oral Diseases; Nanjing Medical University; Nanjing Jiangsu Province China
- Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology; Nanjing Medical University; Nanjing Jiangsu Province China
| | - Guanghui Shi
- Jiangsu Key Laboratory of Oral Diseases; Nanjing Medical University; Nanjing Jiangsu Province China
- Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology; Nanjing Medical University; Nanjing Jiangsu Province China
| | - Ling Xu
- Jiangsu Key Laboratory of Oral Diseases; Nanjing Medical University; Nanjing Jiangsu Province China
- Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology; Nanjing Medical University; Nanjing Jiangsu Province China
| | - Qinyi Gu
- Jiangsu Key Laboratory of Oral Diseases; Nanjing Medical University; Nanjing Jiangsu Province China
| | - Yu Fu
- Jiangsu Key Laboratory of Oral Diseases; Nanjing Medical University; Nanjing Jiangsu Province China
- Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology; Nanjing Medical University; Nanjing Jiangsu Province China
| | - Ping Zhang
- Jiangsu Key Laboratory of Oral Diseases; Nanjing Medical University; Nanjing Jiangsu Province China
- Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology; Nanjing Medical University; Nanjing Jiangsu Province China
| | - Jie Cheng
- Jiangsu Key Laboratory of Oral Diseases; Nanjing Medical University; Nanjing Jiangsu Province China
- Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology; Nanjing Medical University; Nanjing Jiangsu Province China
| | - Hongbing Jiang
- Jiangsu Key Laboratory of Oral Diseases; Nanjing Medical University; Nanjing Jiangsu Province China
- Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology; Nanjing Medical University; Nanjing Jiangsu Province China
| |
Collapse
|
14
|
Magan‐Fernandez A, Fernández‐Barbero JE, O’ Valle F, Ortiz R, Galindo‐Moreno P, Mesa F. Simvastatin exerts antiproliferative and differentiating effects on MG63 osteoblast‐like cells: Morphological and immunocytochemical study. J Periodontal Res 2017; 53:91-97. [DOI: 10.1111/jre.12491] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/05/2017] [Indexed: 11/29/2022]
Affiliation(s)
- A. Magan‐Fernandez
- Department of Periodontics School of Dentistry University of Granada Granada Spain
| | - J. E. Fernández‐Barbero
- Department of Human Anatomy and Embryology School of Medicine (IBIMER, CIBM) University of Granada Granada Spain
| | - F. O’ Valle
- Department of Pathology School of Medicine (IBIMER, CIBM) University of Granada Granada Spain
| | - R. Ortiz
- Department of Human Anatomy and Embryology School of Health Sciences (IBIMER, CIBM) University of Jaen Andalucía Spain
| | - P. Galindo‐Moreno
- Department of Oral Surgery and Implant Dentistry School of Dentistry University of Granada Andalucía Spain
| | - F. Mesa
- Department of Periodontics School of Dentistry University of Granada Granada Spain
| |
Collapse
|
15
|
Wang Z, Wen F, Lim PN, Zhang Q, Konishi T, Wang D, Teoh SH, Thian ES. Nanomaterial scaffolds to regenerate musculoskeletal tissue: signals from within for neovessel formation. Drug Discov Today 2017; 22:1385-1391. [DOI: 10.1016/j.drudis.2017.03.010] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2016] [Revised: 02/20/2017] [Accepted: 03/20/2017] [Indexed: 01/13/2023]
|
16
|
Ungaro F, Catanzano O, d'Angelo I, Diaz-Gomez L, Concheiro A, Miro A, Alvarez-Lorenzo C, Quaglia F. Microparticle-embedded fibroin/alginate beads for prolonged local release of simvastatin hydroxyacid to mesenchymal stem cells. Carbohydr Polym 2017; 175:645-653. [PMID: 28917913 DOI: 10.1016/j.carbpol.2017.08.045] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Revised: 07/31/2017] [Accepted: 08/09/2017] [Indexed: 12/21/2022]
Abstract
In the present work, we propose silk fibroin/alginate (SF/Alg) beads embedding simvastatin-loaded biodegradable microparticles as a versatile platform capable of tuning SVA release and in so doing osteogenic effects. In a first part of the study, microparticles of poly(lactic-co-glycolic) acid incorporating simvastatin either as lactone (SVL) or as hydroxyacid form (SVA) were prepared by spray-drying. While SVA-loaded microparticles released the drug in three days, long-term release of SVA could be obtained from SVL-loaded microparticles. In this latter case, SVL was promptly transformed to the osteogenic active SVA during release. When tested on mesenchymal stem cells, a time- and dose-dependent effect of SVL-loaded microparticles on cell proliferation and alkaline phosphatase (ALP) activity was found. Thereafter, SVL-loaded microparticles were embedded in SF/Alg beads to limit the initial simvastatin burst and to achieve easier implantation as well. Microparticle-embedded beads showed no cytotoxicity while ALP activity increased. If correctly exploited, the developed system may be suitable as osteogenic polymer scaffolds releasing correct amount of the drug locally for long time-frames.
Collapse
Affiliation(s)
- F Ungaro
- Drug Delivery Laboratory, Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy
| | - O Catanzano
- Drug Delivery Laboratory, Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy
| | - I d'Angelo
- Di.S.T.A.B.i.F., University of Campania "Luigi Vanvitelli", Via Vivaldi 43, 81100 Caserta, Italy
| | - L Diaz-Gomez
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+D Pharma Group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - A Concheiro
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+D Pharma Group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - A Miro
- Drug Delivery Laboratory, Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy.
| | - C Alvarez-Lorenzo
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+D Pharma Group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
| | - F Quaglia
- Drug Delivery Laboratory, Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy
| |
Collapse
|
17
|
Martin V, Bettencourt A. Bone regeneration: Biomaterials as local delivery systems with improved osteoinductive properties. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2017; 82:363-371. [PMID: 29025670 DOI: 10.1016/j.msec.2017.04.038] [Citation(s) in RCA: 92] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/28/2017] [Revised: 04/05/2017] [Accepted: 04/06/2017] [Indexed: 12/15/2022]
Abstract
Bone is a mineralized conjunctive tissue, with a unique trauma healing capability. However, the replacement or regeneration of lost bone is not always successful and becomes more difficult the wider the bone defect. A significant growth in the demand for orthopedic and maxillofacial surgical procedures as a result of population aging and increase in chronic diseases as diabetes is a fact and successful approaches for bone regeneration are still needed. Until today, autogenous bone graft continues to be the best solution even with important limitations, as quantity and the requirement of a donator area. Alternatively, local delivery systems combining an osteoconductive biomaterial with osteoinductive compounds as hormones, growth factors or drugs is a popular approach aiming to replace the need for autogenous bone grafts. Nevertheless, in spite of the intense research in the area, presently there is no system that can mimic all the biological functions of the autogenous bone grafts. In this context, the present work provides an overview of the most recent advances in the field of synthetic bone grafts. The opportunities and limitations are detailed along with the remaining gaps in the research that are still preventing the successful translation of more products into the market able to be a valuable option in comparison to the autogenous bone grafts.
Collapse
Affiliation(s)
- Victor Martin
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal
| | - Ana Bettencourt
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal.
| |
Collapse
|
18
|
Ahmad N, Banala VT, Kushwaha P, Karvande A, Sharma S, Tripathi AK, Verma A, Trivedi R, Mishra PR. Quercetin-loaded solid lipid nanoparticles improve osteoprotective activity in an ovariectomized rat model: a preventive strategy for post-menopausal osteoporosis. RSC Adv 2016. [DOI: 10.1039/c6ra17141a] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
A formulation of quercetin-based solid lipid nanoparticles (QSLNs) was developed to increase the bioavailability of quercetin, with an aim to evaluate its effects on bone health in comparison to free quercetin (Q).
Collapse
Affiliation(s)
- Naseer Ahmad
- Division of Endocrinology
- Central Drug Research Institute (Council of Scientific and Industrial Research)
- Lucknow 226031
- India
| | - Venkatesh Teja Banala
- Division of Pharmaceutics
- Central Drug Research Institute (Council of Scientific and Industrial Research)
- Lucknow 226031
- India
| | - Priyanka Kushwaha
- Division of Endocrinology
- Central Drug Research Institute (Council of Scientific and Industrial Research)
- Lucknow 226031
- India
| | - Anirudha Karvande
- Division of Endocrinology
- Central Drug Research Institute (Council of Scientific and Industrial Research)
- Lucknow 226031
- India
| | - Shweta Sharma
- Division of Pharmaceutics
- Central Drug Research Institute (Council of Scientific and Industrial Research)
- Lucknow 226031
- India
| | - Ashish Kumar Tripathi
- Division of Endocrinology
- Central Drug Research Institute (Council of Scientific and Industrial Research)
- Lucknow 226031
- India
| | - Ashwni Verma
- Division of Pharmaceutics
- Central Drug Research Institute (Council of Scientific and Industrial Research)
- Lucknow 226031
- India
| | - Ritu Trivedi
- Division of Endocrinology
- Central Drug Research Institute (Council of Scientific and Industrial Research)
- Lucknow 226031
- India
| | - Prabhat Ranjan Mishra
- Division of Pharmaceutics
- Central Drug Research Institute (Council of Scientific and Industrial Research)
- Lucknow 226031
- India
| |
Collapse
|